Gelonghui, April 25, 丨 Sihuan Pharmaceutical (00460.HK) announced that on April 23, 2024, Huisheng Biopharmaceutical Co., Ltd., a non-wholly-owned subsidiary of the Group, participated in the national centralized drug procurement (insulin special continuation) declaration work organized by the State Organization Drug Joint Procurement Office. The three products developed by Huisheng Biotech, Mendon Insulin 30 Injection, and Menton Insulin 50 Injection were eligible for selection in this special succession of insulin purchases, and they all plan to select Class A varieties. The current centralized insulin procurement cycle began on the date of implementation of the selection results and ended on December 31, 2027.
Insulin is a third-generation fast-acting insulin analog. It works within 10-20 minutes after subcutaneous injection. It can better control blood sugar after meals, reduce the risk of hypoglycemia, and is more flexible. It can be injected during meals, and can also be used for insulin pumps and intravenous injections. Insulin 30/50 injection is a biphasic insulin composed of 30%/50% soluble amdol insulin and 70%/50% refined protein medon insulin. It can better control blood sugar on an empty stomach and after meals, reduce the number of injections, and has obvious advantages in improving compliance and saving medical costs. Since it has two different ratios, clinicians can provide patients with more flexible and personalized treatment options according to the patient's post-meal blood sugar level.
The three products developed by Huisheng Biotech, Mendon Insulin 30 Injection, and Mendong Insulin 50 Injection were approved for listing by the National Drug Administration (NMPA) on December 26, 2023. As new entrants, this collection will facilitate the sale of Huisheng Biotech insulin analogue products, accelerate product entry, increase market share, and have a positive impact on enhancing Huisheng Biotech's brand influence and future long-term development. At the same time, it will further enhance the accessibility of insulin products to benefit the majority of patients in China.